知镜 Cognispect · 医学文献与研究工作台

Interleukin-37 overexpression enhances the therapeutic efficacy of adipose-derived mesenchymal stem cells in atopic dermatitis by activating autophagy and improving skin barrier dysfunction.

Chen W, Li S, Guo X, Hu F, Wang Q, Zhang X, Xiao F, Zhang J, Liang J.
The Journal of pharmacology and experimental therapeutics · 2026-09-21 · PMID 42880197

文献摘要

Adipose-derived mesenchymal stem cells (ADSCs) have emerged as a promising therapeutic option because of their immunomodulatory and tissue-repair capabilities in the treatment of Atopic dermatitis (AD). However, their efficacy is limited by cellular senescence and functional decline. Interleukin-37 (IL-37), an anti-inflammatory cytokine, has shown potential in mitigating inflammation and enhancing skin barrier function. This study investigated whether IL-37 overexpression in ADSCs could augment their therapeutic effects in AD and the underlying mechanism. Lentiviral-mediated IL-37 overexpression in ADSCs enhanced proliferation, reduced senescence (evidenced by decreased β-galactosidase activity), and activated autophagy, as shown by elevated LC3B-II/I and Beclin-1 levels, reduced p62, and increased LC3B puncta formation. These effects were reversed by the autophagy inhibitor 3-MA. In an IL-4/IL-13-induced HaCaT cell model of AD, coculture with IL-37-overexpressing ADSCs promoted keratinocyte proliferation, reduced apoptosis, suppressed proinflammatory cytokines (IL-1β, IL-6, tumor necrosis factor-α, thymus and activation-regulated chemokine), and restored the expression of skin barrier proteins (Filaggrin, Involucrin). In vivo, local injection of IL-37-overexpressing ADSCs into lesional skin in a 2,4-dinitrochlorobenzene-induced AD mouse model attenuated skin lesions, reduced inflammation, and improved barrier protein expression. These results demonstrate that IL-37 overexpression enhances the therapeutic efficacy of ADSCs in AD through autophagy activation and restoration of skin barrier function, providing a novel genetically engineered stem cell-based strategy for the treatment of AD. SIGNIFICANCE STATEMENT: IL-37-engineered adipose-derived mesenchymal stem cells improve atopic dermatitis treatment by activating autophagy to reduce senescence and enhance proliferation. These cells suppress inflammation while restoring skin barrier proteins, providing a novel therapy for refractory skin diseases.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。